EP0082731A1 — The use of peptides as medicaments
Assigned to Novo Nordisk AS · Expires 1983-06-29 · 43y expired
What this patent protects
Certain glucagon derivatives containing the glucagon moiety His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp- connected to hydroxy or one of the peptid chains -Phe-Val-Gln-Trp-Leu or -Met-Asn-Thr or one of the last two peptide chains with one or…
USPTO Abstract
Certain glucagon derivatives containing the glucagon moiety His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp- connected to hydroxy or one of the peptid chains -Phe-Val-Gln-Trp-Leu or -Met-Asn-Thr or one of the last two peptide chains with one or more of the amino acids therein left out, have an insulin releasing effect under hyperglycaemia conditions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.